A comparative evaluation of efficacy of chemotherapy, immunotherapy and immunochemotherapy in visceral leishmaniasis-an experimental study

Parasitology International

Volumn 63, Issue 4, 2014, Pages 612-620

  Joshi, Jyoti ^a   Malla, Nancy ^b   Kaur, Sukhbir ^a  

^a PANJAB UNIVERSITY   (India)

^b POSTGRADUATE INSTITUTE OF MEDICAL EDUCATION AND RESEARCH   (India)

Author keywords

Immunochemotherapy; Killed Leishmania donovani antigen; MPL A (Monophosphoryl lipid A); Sodium stibogluconate; Visceral leishmaniasis

Indexed keywords

CISPLATIN; GAMMA INTERFERON; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2A; INTERLEUKIN 10; INTERLEUKIN 4; LEISHMANIA VACCINE; STIBOGLUCONATE SODIUM; ANTIPARASITIC AGENT; IMMUNOGLOBULIN G;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ARTICLE; CHEMOTHERAPY; CONTROLLED STUDY; CYTOKINE RESPONSE; DELAYED HYPERSENSITIVITY; DRUG EFFICACY; DRUG FORMULATION; DRUG POTENCY; IMMUNE RESPONSE; IMMUNOCHEMOTHERAPY; IMMUNOTHERAPY; IN VIVO STUDY; LEISHMANIA DONOVANI; MONOTHERAPY; MOUSE; MULTIPLE CYCLE TREATMENT; NONHUMAN; PARASITE LOAD; PRIORITY JOURNAL; PROMASTIGOTE; TH1 CELL; VISCERAL LEISHMANIASIS; ANIMAL; BAGG ALBINO MOUSE; BIOSYNTHESIS; DRUG EFFECTS; IMMUNOLOGY; LEISHMANIASIS, VISCERAL; PARASITOLOGY;

ANIMALS; ANTIPARASITIC AGENTS; HYPERSENSITIVITY, DELAYED; IMMUNOGLOBULIN G; IMMUNOTHERAPY; LEISHMANIA DONOVANI; LEISHMANIASIS VACCINES; LEISHMANIASIS, VISCERAL; MICE; MICE, INBRED BALB C; PARASITE LOAD;

EID: 84899855412     PISSN: 13835769     EISSN: 18730329     Source Type: Journal    
DOI: 10.1016/j.parint.2014.04.002     Document Type: Article

References (39)

1. Evans K.J., Kedzierski L. Development of vaccines against visceral leishmaniasis. J Trop Med 2012, 2012:892817.
2. Mondal S., Bhattacharya P., Rahaman M., Ali N., Goswami R.P. A curative immune profile one week after treatment of Indian kalaazar patients predicts success with a short-course liposomal amphotericin B therapy. PLoS Negl Trop Dis 2010, 4:e764.
3. Mayrink W., da Costa C.A., Magalhaes P.A., Melo M.N., Dias M., Lima A.O., et al. A field trial of a vaccine against American Dermal Leishmaniasis. Trans R Soc Trop Med Hyg 1979, 73:385-387.
4. Mayrink W., Williams P., da Costa C.A., Magalhaes P.A., Melo M.N., Dias M., et al. An experimental vaccine against American dermal leishmaniasis: experience in the state of Espírito Santo, Brazil. Ann Trop Med Parasitol 1985, 79:259-269.
5. Convit J., Ulrich M., Polegre M.A., Avila A., Rodriguez N., Mazzedo M.I., et al. Therapy of Venezuelan patients with severe mucocutaneous or early lesions of diffuse cutaneous leishmaniasis with a vaccine containing pasteurized Leishmania promastigotes and Bacillus calmette-Guerin - Preliminary Report. Mem Inst Oswaldo Cruz 2004, 99:57-62.
6. Nagill R., Mahajan R., Sharma M., Kaur S. Induction of cellular and humoral responses by autoclaved and heat-killed antigen of Leishmania donovani in experimental visceral leishmaniasis. Parasitol Int 2009, 58:359-366.
7. Ulrich J.T., Myers K.R. Monophosphoryl A as an adjuvant. Vaccine design: the subunit and adjuvant approach 1995, 495. Plenum Press, New York. M.F. Powel, M.J. Newman (Eds.).
8. Tewary P., Sukumaran B., Saxena S., Madhubala R. Immunostimulatory oligodeoxynucleotides are potent enhancers of protective immunity in mice immunized with recombinant ORFF leishmanial antigen. Vaccine 2004, 22:3053-3060.
9. Perez-Victoria F.J., Castanys S., Gamarro F. Leishmania donovani resistance to miltefosine involves a defective inward translocation of the drug. Antimicrob Agents Chemother 2003, 47:2397-3303.
10. Kaur S., Sachdeva H., Dhuria S., Sharma M., Kaur T. Antileishmanial effect of cisplatin against murine visceral leishmaniasis. Parasitol Int 2010, 59:62-69.
11. Sharma M., Sehgal R., Kaur S. Evaluation of nephroprotective and immunomodulatory activities of antioxidants in combination with cisplatin against murine visceral leishmaniasis. PLoS Negl Trop Dis 2012, 6:e1629.
12. Musa A.M., Noazin S., Khalil E.A., Modabber F. Immunological stimulation for the treatment of leishmaniasis: a modality worthy of serious consideration. Trans R Soc Trop Med Hyg 2010, 104:1-2.
13. Bhakuni V., Kulkarni S., Ali V., Singh U.K., Levy H.B., Maheshwari R.K. Immunochemotherapy for Leishmania donovani Infection in golden hamsters: combinatorial Action of poly ICLC plus L-arginine and sodium stibogluconate (Stibanate). J Interferon Cytokine Res 1999, 19:1103-1106.
14. Miret J., Nascimento E., Sampaio W., Franca J.C., Fujiwara R.T., Vale A., et al. Evaluation of an immunochemotherapeutic protocol constituted of N-methyl meglumine antimoniate (Glucantime) and the recombinant Leish-110f+MPL-SE vaccine to treat canine visceral leishmaniasis. Vaccine 2008, 26:1585-1594.
15. Rao R.R., Mahajan R.C., Ganguly N.K. Modified media for in vitro cultivation of Leishmania promastigotes. A comparative study. Bull Postgrad Inst 1984, 18:125-128.
16. Sodhi S., Kaur S., Mahajan R.C., Ganguly N.K., Malla N. Effect of sodium stibogluconate and pentamidine on in vitro multiplication of Leishmania donovani in peritoneal macrophages from infected and drug- treated BALB/c mice. Immunol Cell Biol 1992, 70:25-31.
17. Bradley D.J., Kirkley J. Regulation of Leishmania population within host 1. The variable course of L. donovani infections in mice. Clin Exp Immunol 1977, 30:119-129.
18. Kaur S., Kaur T., Garg N., Mukherjee S., Raina P., Athokpam V. Effect of dose and route of inoculation on the generation of CD4+ Th1/Th2 type of immune response in murine visceral leishmaniasis. Parasitol Res 2008, 103(6):1413-1419.
19. Kedzierski L. Leishmaniasis vaccine: Where are we today?. J Global Infect Dis 2010, 2:177-185.
20. Borja-Cabrera G.P., Santos F.N., Santos F.B., Trivellato F.A., Kawasaki J.K., Costa A.C., et al. Immunotherapy with the saponin enriched-Leishmune vaccine versus immunochemotherapy in dogs with natural canine visceral leishmaniasis. Vaccine 2010, 28(3):597-603.
21. Murray H.W., Brooks E.B., DeVecchio J.L., Heinzel F.P. Immunoenhancement combined with Amphotericin B as treatment for experimental visceral leishmaniasis. Antimicrob Agents Chemother 2003, 47(8):2513-2517.
22. Mazumder S., Maji M., Das A., Ali N. Potency, efficacy and durability of DNA/DNA, DNA/protein and protein/protein based vaccination using gp63 against Leishmania donovani in BALB/c mice. PLoS One 2011, 6(2):e14644.
23. Neogy A.B., Nandy A., Ghosh Dastidar B., Chowdhury A.B. Antibody kinetics in kala-azar in response to treatment. Ann Trop Med Parasitol 1987, 81:727-729.
24. Anam K., Afrin F., Banerjee D., Pramanik N., Guha S.K., Goswami R.P., et al. Differential decline in Leishmania membrane antigen-specific immunoglobulin G (IgG), IgM, IgE, and IgG subclass antibodies in Indian kala-azar patients after chemotherapy. Infect Immun 1999, 67:6663-6669.
25. Abbas A.K., Murphy K.M., Sher A. Functional diversity of helper T lymphocytes. Nature 1996, 383:787-793.
26. Rothman P., Coffman R.L. Immunoglobulin heavy chain class switching. Weir's handbook of experimental immunology 1996, Blackwell Scientific Publications, Oxford, United Kingdom, [19.1-19.4 pp.]. 5th ed. L.A. Herzenberg (Ed.).
27. Murray H.W., Oca M.J., Granger A.M., Schreiber R.D. Requirement for T cells and effect of lymphokines in successful chemotherapy for an intracellular infection. J Clin Invest 1989, 83:1253-1257.
28. Tacchini-Cottier F., Weinkopff T., Launois P. Does T helper differentiation correlate with resistance or susceptibility to infection with L. major? Some insights from the murine model. Front Immunol 2012, 3:32.
29. Heinzel F.P., Sadick M.D., Holaday B.J., Coffman R.L., Locklsey R.M. Reciprocal expression of interferon gamma or interleukin 4 during the resolution or progression of murine leishmaniasis. Evidence for expansion of distinct helper T cells subsets. J Exp Med 1989, 169:59-72.
30. Miralles G.D., Stoeckle M.Y., McDermott D.F., Finkelman F.D., Murray H.W. Th1 and Th2 cell-associated cytokines in experimental visceral leishmaniasis. Infect Immun 1994, 62:1058-1063.
31. Kemp M., Theander T.G., Kharazmi A. The contrasting roles of CD4+ T cells in intracellular infections in humans: leishmaniasis as an example. Immunol Today 1996, 17:13-16.
32. Bhowmick S., Ravindran R., Ali N. gp63 in stable cationic liposomes confers sustained vaccine immunity to susceptible BALB/c mice infected with Leishmania donovani. Infect Immun 2008, 76:1003-1015.
33. Varma N., Naseem S. Hematologic changes in visceral leishmaniasis/Kala Azar. Indian J Hematol Blood Transfus 2010, 26:78-82.
34. Das V.N.R., Ranjan A., Bimal S., Siddique N.A., Pandey K., Kumar N., et al. Magnitude of unresponsiveness to sodium stibogluconate in the treatment of visceral leishmaniasis in Bihar. Nat Med J 2005, 18:131-133.
35. al Khawajah A., Larbi E.B., Jain S., al-Gindan Y., Abahussain A. Subacute toxicity of pentavalent antimony compounds in rats. Hum Exp Toxicol 1992, 11:283-288.
36. Sundar S., Jha T.K., Thakur C.P., Sinha P.K., Bhattacharya S.K. Injectable paromomycin for visceral leishmaniasis in India. N Engl J Med 2007, 356:2571-2581.
37. Waikar S.S., Wald R., Chertow G.M., Curhan G.C., Winkelmayer W.C., Liangos O., et al. Validity of International Classification of Diseases, Ninth Revision, and Clinical Modification codes for acute renal failure. J Am Soc Nephrol 2006, 17:1688-1694.
38. Yao X., Panichpisal K., Kurtzman N., Nugent K. Cisplatin nephrotoxicity: A review. Am J Med Sci 2007, 334:115-124.
39. Kashani M.N., Firooz A., Eskandari S.E., Ghoorchi M.H., Khamesipour A., Khatami A., et al. Evaluation of meglumine antimoniate effects on liver, kidney and pancreas function tests in patients with cutaneous leishmaniasis. Eur J Dermatol 2007, 17:513-515.